Morniflu (Morniflumate)

Morniflumate exerts its effect by reversibly inhibiting cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are key in the conversion of arachidonic acid to prostaglandins. By reducing prostaglandin synthesis, it diminishes inflammation, pain, and fever associated with musculoskeletal disorders.

The dosage of Morniflu is individualized; the prescribing healthcare professional determines the appropriate strength, frequency, and duration based on the patient’s condition, age, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for morniflumate during pregnancy and lactation are limited. As with most NSAIDs, it is generally advised to avoid use in the third trimester of pregnancy due to potential fetal complications, and caution is recommended while breastfeeding. The prescriber should evaluate risks versus benefits for each patient.

To request Morniflu, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Morniflumate belongs to the same class of non‑steroidal anti‑inflammatory drugs as ibuprofen, diclofenac and naproxen, sharing a similar mechanism of COX inhibition. Compared with some NSAIDs, morniflumate may have a slightly different gastrointestinal tolerability profile, but overall efficacy and safety are comparable and must be assessed individually.

Morniflu should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Morniflu is supplied as an oral dosage form that should be taken with a full glass of water. It can be taken with or without food, although taking it with meals may reduce gastrointestinal discomfort. The exact dosing schedule is set by the prescribing clinician.

The most serious adverse events associated with morniflumate include gastrointestinal ulceration or bleeding, severe allergic reactions such as anaphylaxis, hepatic injury, and renal impairment. Patients should be advised to seek immediate medical attention if they experience black stools, unexplained abdominal pain, jaundice, swelling, or signs of an allergic reaction.

Morniflu is contraindicated in individuals with known hypersensitivity to morniflumate or other NSAIDs, those with active peptic ulcer disease, severe heart failure, or significant hepatic or renal impairment. It should also be avoided in patients who are in the third trimester of pregnancy. The prescribing clinician must evaluate each patient’s medical history before initiating therapy.